Please turn JavaScript on

Dr. Chapa’s OBGYN Clinical Pearls

Want to stay in touch with the latest updates from Dr. Chapa’s OBGYN Clinical Pearls? That's easy! Just subscribe clicking the Follow button below, choose topics or keywords for filtering if you want to, and we send the news to your inbox, to your phone via push notifications or we put them on your personal page here on follow.it.

Reading your RSS feed has never been easier!

Website title: Brand Logo

Is this your feed? Claim it!

Publisher:  Unclaimed!
Message frequency:  0.33 / day

Message History

Welcome back to the show. Let’s take a quick step back in time. Think about how far we’ve come: we went from pressing a classic OB fetoscope up against a pregnant belly just to catch a faint, muffled thumping, to relying on advanced, continuous electronic monitoring. We live in an era of high-tech obstetrics. But even with all these modern advancements, room for error still e...


Read full story

Now, if you’ve been in OB care for more than a month, you know that preeclampsia is one of those topics we talk about constantly. We have endless guidelines, algorithms, and diagnostic criteria plastered all over our unit walls. But here’s the truth: despite all the literature out there, the real world doesn't always read the textbook. The clinical nuances… The gray areas…Tha...


Read full story

Yes, we have covered cervical cancer screening many, many times on this show. It is truly a testament to science and research just how far we have come from using slide-based cytology for cervical cancer screening. Primary high-risk HPV, as a screening modality, has been favored for many years and is now officially part of the age-based, ACOG cervical cancer screening guideli...


Read full story

If you work in women’s health, you already know the golden rule: just when you think you’ve got a guideline memorized, the ink dries, and the updates drop. Medicine moves fast, and this month is no exception. Today, we are diving straight into the fresh-off-the-press October 2026 ACOG Practice Advisory on Premature Ovarian Insufficiency. Now, if you’re thinking, 'Wait, didn’t...


Read full story

Back in 2021, we discussed the FDA approval of a combination GNRH antagonist (relagolix) with estradiol and norethindrone. This was originally approved to treat uterine fibroid related heavy menstrual bleeding. It is also now approved for endometriosis care. In theory, this should also be an effective contraceptive agent. However, the FDA label strictly cautions against its u...


Read full story